Inside Haematologica: caution in the use of thalidomide for treatment of hematologic disorders.

by thalidomide requires metabolic activation, which is species dependent. Biochem Pharmacol 1998; 55: 182734. 10. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high grade gliomas. J Clin Oncol 2000; 18:708-15. 11. Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG, et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 2000; 18:2710-7. 12. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, et al. Continuous low dose thalidomide: phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000; 82: 812-7. 13. Figg WD, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan R, et al. Pharmacokinetics of thalidomide in an elderly prostate cancer population. J Pharmacol Sci 1999; 88: 121-5. 14. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, et al. Activity of thalidomide in AIDS-related Kaposi’s sarcoma. J Clin Oncol 2000; 18: 2593-602. 15. Cheng D, Kini AR, Rodriguez J, Burt R, Pereson LC, Traynor AE. Microvascular density and cytotoxic T cell activation correlate with response to thalidomide in multiple myeloma patients. Blood 1999; 94(suppl. 1):317a. 16. Rajkumar SV, Timm M, Mesa RA et al. Effect of thalidomide on myeloma cell apoptosis and VEGF secretion. Blood 2000; 96 (suppl. 1):364a. 17. Weber DM, Rankin K, Gavino M, et al., Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma. Blood 2000; 96(suppl. 1):168a. 18. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996; 31:213-21. 19. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991; 173:699-703. 20. McHugh SM, Rifkin IR, Deighton J, Wilson AB, Lachmann PJ, Lockwood CM, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th 2) and concomitantly inhibits TH1 cytokine production in mitogen – and antigen – stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995; 99: 160-7.